Skip to main content
Clinical Trials/NL-OMON20183
NL-OMON20183
Not Yet Recruiting
N/A

The treatment of patients with a clinically SUspected ScaPhoid fracturE: bandage or a CasT

Erasmus MC0 sites180 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
clinical suspected scaphoid fracture. Klinische verdenking scaphoid fractuur
Sponsor
Erasmus MC
Enrollment
180
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Erasmus MC

Eligibility Criteria

Inclusion Criteria

  • age minimally 18 years, maximum 48 hours post trauma, clinically suspected scaphoid fracture (pain tabatiere anatomique or tuberculum scaphoideum), no fracture on initial radiographs

Exclusion Criteria

  • Concomitant injuries to the ipsilateral upper extremity, insufficient command of the Dutch language

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaMedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-003430-13-IEChildren's Oncology Group9,483
Recruiting
N/A
Investigation of clinical course and treatment of acute exacerbation of interstitial lung disease - A Prospective Observational Study
JPRN-UMIN000043154Hamamatsu University School of Medicine400
Suspended
N/A
Elucidation of pathologic condition in patients with cerebrovascular disease or neurodegenerative disease using C-11 flumazenil PETPatients with or suspected cerebrovascular disease or neurodegenerative disease
JPRN-UMIN000043740Kagawa University30
Completed
Phase 3
Maha analuruva chooranam (internal) and Chennagarapattai ennai (external)for the management of Baalavatham(Paresis) in childreHealth Condition 1: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere
CTRI/2021/08/035549ational Institute of Siddha30
Completed
N/A
sing two drugs in combination at the start of drug treatment for type 2 diabetes vs using a single drug
ISRCTN26805203Pakistan Institute of Medical Sciences285